Zydus Lifesciences Shares Slide Over 2% on USFDA Warning Letter for Baddi Plant

$ZYDUSLIFE ces stock declined more than 2% on Wednesday after the company received a warning letter from the US Food and Drug Administration (USFDA) for its formulation manufacturing facility in Baddi, Himachal Pradesh. The regulatory action pertains to observations related to purified talc not meeting United States Pharmacopeia (USP) standards. The letter was issued based on a review of records and not a physical inspection of the site. In a regulatory filing, Zydus stated that the warning letter will not impact current operations or product supplies from the Baddi facility. The company said it is committed to addressing the concerns raised by the USFDA and maintaining the highest quality standards.